ストックスクリーナーアプリを入手
3.94
0.00%
0.00
前日終値:
$3.94
開ける：
$3.96
24時間の取引高:
44,104
Relative Volume:
0.86
時価総額：
$4.91M
収益：
$12.99M
当期純損益:
$-27.83M
株価収益率:
-0.0193
EPS:
-203.7366
ネットキャッシュフロー:
$-26.98M
1週間 パフォーマンス:
-11.86%
1か月 パフォーマンス:
-16.53%
6か月 パフォーマンス:
-59.21%
1年 パフォーマンス:
-92.73%
1日の値動き範囲:
$3.79
$3.96
1週間の範囲:
$3.6803
$4.79
52週間の値動き範囲:
$3.6803
$59.40
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Compare APVO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
3.94 | 4.91M | 12.99M | -27.83M | -26.98M | -203.74 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2018-11-05 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-10-05 | 再開されました | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc (APVO) 最新ニュース
Aptevo Therapeutics Inc (APVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aptevo Therapeutics (APVO) Edges Higher: Testing Key Resistance Amid Steady VolumeBPI Reversal - dars.gov.et
Aptevo Therapeutics Secures Grant for APVO451 Development - The Globe and Mail
Grant supports Aptevo’s immunotherapy APVO-451 for solid tumors - BioWorld News
Aptevo (NASDAQ: APVO) gets $1.5M CARE Fund grant to advance APVO451 - Stock Titan
Aptevo receives $1.5M grant for cancer therapy development - Investing.com
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors - The Joplin Globe
Price to sales forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Price to sales forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView
Aptevo Therapeutics (APVO) Edges Lower, Testing Key Support LevelsFlat Correction - dars.gov.et
Price to book forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
APVO Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Enterprise value to EBIT forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Price to earnings forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView
Aptevo Therapeutics, Inc. Actuals & Estimates (NASDAQ:APVO) - TradingView
Aptevo Therapeutics, Inc. Actuals & Estimates (MUN:AP82) - TradingView
Aptevo Therapeutics, Inc. Actuals & Estimates (FWB:AP82) - TradingView
AP82 Forecast — Price Target — Prediction for 2027 - TradingView
Aptevo Therapeutics Inc (APVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 13G Aptevo Therapeutics Inc. For: 22 June By Investing.com - Investing.com South Africa
Niowave holds 12.18% of Aptevo (NASDAQ: APVO) — 151,723 shares - Stock Titan
NIOWAVE, INC. (NASDAQ: APVO) discloses 98,522 shares and $8 warrants - Stock Titan
Aptevo Therapeutics Inc (APVO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aptevo Therapeutics Inc (APVO) Institutional Confidence - TradingKey
Aptevo Therapeutics Inc (APVO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aptevo Therapeutics Inc (APVO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aptevo Therapeutics Inc (APVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aptevo Therapeutics Inc (APVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aptevo Therapeutics Inc (APVO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aptevo and Niowave Partner to Advance Radiopharmaceutical Cancer Therapies - citybuzz -
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category - NewMediaWire
Aptevo reports 87% clinical benefit rate in AML trial - Investing.com
- The Legal Advocate
Aptevo Therapeutics (APVO) Slips 1.43% as Shares Test Key Support Near $4.66Butterfly Setup - The Legal Advocate
Aptevo Therapeutics (APVO) Holds Near Support After Modest DeclineHedge Fund Favorites - dars.gov.et
Aptevo Therapeutics Dip Continues as Stock Consolidates Near Key SupportBuffered ETF - The Legal Advocate
Aptevo Therapeutics (APVO) Slides Lower as Support Level Comes Into FocusFibonacci Retracement - The Legal Advocate
APVO Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Faces HeadwindsPretax Income Report - newsline.com
Aptevo Therapeutics (APVO) SVP, CSO files Form 3 reporting zero shares - Stock Titan
Aptevo names Mary Janatpour as chief scientific officer - Investing.com UK
Aptevo Therapeutics Names Mary Janatpour Chief Scientific Officer as It Expands Beyond Core Immuno-Oncology Programs - citybiz
Aptevo names Mary Janatpour as chief scientific officer By Investing.com - Investing.com Nigeria
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer - ACCESS Newswire
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing - Black Hills Pioneer
Seattle biotech lands investment, collaboration deal for cancer treatments - The Business Journals
Aptevo and Niowave Partner to Develop Radiopharmaceuticals; Niowave to Invest in Aptevo - geneonline.com
Aptevo Forms Strategic Radiopharmaceutical Collaboration with Niowave - TipRanks
Aptevo Therapeutics (APVO) Forms Strategic Collaboration with Ni - GuruFocus
APVO Q1 2026 Earnings: EPS Miss Widens as Revenue Remains AbsentEarnings Preview - The Legal Advocate
Aptevo and Niowave launch radiopharmaceuticals collaboration - The Pharma Letter
Aptevo Therapeutics Inc (APVO) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):